Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760

Watchlist Manager
Shenzhen Mindray Bio-Medical Electronics Co Ltd Logo
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Watchlist
Price: 263.31 CNY -3.2% Market Closed
Market Cap: 318.7B CNY
Have any thoughts about
Shenzhen Mindray Bio-Medical Electronics Co Ltd?
Write Note

Shenzhen Mindray Bio-Medical Electronics Co Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Mindray Bio-Medical Electronics Co Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Other Current Liabilities
ÂĄ5B
CAGR 3-Years
13%
CAGR 5-Years
19%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Other Current Liabilities
ÂĄ331.4m
CAGR 3-Years
105%
CAGR 5-Years
109%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Other Current Liabilities
ÂĄ587.7m
CAGR 3-Years
-10%
CAGR 5-Years
8%
CAGR 10-Years
26%
J
Jafron Biomedical Co Ltd
SZSE:300529
Other Current Liabilities
ÂĄ318.2m
CAGR 3-Years
24%
CAGR 5-Years
15%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Other Current Liabilities
ÂĄ514.6m
CAGR 3-Years
-12%
CAGR 5-Years
-15%
CAGR 10-Years
14%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Other Current Liabilities
ÂĄ3B
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Mindray Bio-Medical Electronics Co Ltd
Glance View

Market Cap
319.2B CNY
Industry
Health Care

Shenzhen Mindray Bio-Medical Electronics Co., Ltd., founded in 1991, has evolved into a leading global player in the medical device industry, with a compelling story of innovation and resilience at its core. Originating from the bustling tech hub of Shenzhen, the company specializes in developing and manufacturing high-quality medical equipment and solutions, particularly in the fields of imaging, in-vitro diagnostics, and patient monitoring. Mindray's commitment to advanced research and development has led it to achieve a strong competitive edge, enabling it to penetrate international markets and establish partnerships with healthcare providers across over 190 countries. With an unwavering focus on improving healthcare outcomes, Mindray is positioned not just as a manufacturer, but as a trusted partner in enhancing patient care worldwide. As an investor, you would be interested to know that Mindray's growth trajectory has been remarkable, characterized by steady revenue increases and robust profitability. The company's diversified product portfolio, including vital sign monitors, ultrasound systems, and laboratory solutions, addresses a wide array of healthcare needs, making it resilient to market fluctuations. Moreover, in response to the growing global emphasis on healthcare quality, Mindray continuously expands its innovations, investing significantly in R&D and leveraging advanced technologies like artificial intelligence. With a strong balance sheet and a commitment to ethical business practices, Mindray not only seeks to drive strong financial performance but also aims to foster a sustainable impact on global health, making it an attractive prospect for forward-thinking investors aiming to align their portfolios with socially responsible investments.

Intrinsic Value
360.5 CNY
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Shenzhen Mindray Bio-Medical Electronics Co Ltd's Other Current Liabilities?
Other Current Liabilities
5B CNY

Based on the financial report for Jun 30, 2024, Shenzhen Mindray Bio-Medical Electronics Co Ltd's Other Current Liabilities amounts to 5B CNY.

What is Shenzhen Mindray Bio-Medical Electronics Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
19%

Over the last year, the Other Current Liabilities growth was -1%. The average annual Other Current Liabilities growth rates for Shenzhen Mindray Bio-Medical Electronics Co Ltd have been 13% over the past three years , 19% over the past five years .

Back to Top